Scarica l'app Stockscreener
17.97
6.39%
1.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.89
Aprire:
$17.16
Volume 24 ore:
923.87K
Relative Volume:
1.24
Capitalizzazione di mercato:
$1.47B
Reddito:
$288.00K
Utile/perdita netta:
$-228.06M
Rapporto P/E:
-4.2282
EPS:
-4.25
Flusso di cassa netto:
$-168.82M
1 W Prestazione:
+3.04%
1M Prestazione:
+5.46%
6M Prestazione:
+2.86%
1 anno Prestazione:
+17.53%
Intervallo 1D:
$16.95
$18.04
Intervallo di 1 settimana:
$15.68
$18.04
Portata 52W:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta VRDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
17.97 | 1.38B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Evercore ISI Maintains Buy Rating on Viridian Therapeutics with $38 Price Target - AInvest
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating - TipRanks
Goldman Sachs Raises Price Target for Viridian Therapeutics (VRDN) to $30: Analysts' Forecasts and Ratings. - AInvest
Viridian Therapeutics Q2 Results Beat Expectations, Analysts Revise Forecasts - AInvest
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
Oppenheimer Boosts Viridian Therapeutics' Target Price to $32.00, Maintaining 'Outperform' Rating. - AInvest
Wells Fargo Lowers Viridian Therapeutics Price Target to $26, Keeps Equal Weight Rating - AInvest
Viridian: Oppenheimer raises PT to $32 from $28, maintains Outperform rating. - AInvest
RBC Lowers Price Target on Viridian Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk - MarketScreener
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo - TipRanks
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Viridian Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments - TipRanks
Viridian (VRDN) Reports Q2 Revenue Surpassing Estimates, Cash Position Supports Operations into 2027. - AInvest
Viridian Therapeutics Grants Inducement Stock Options to New Employees - AInvest
Viridian Therapeutics: Hold Rating and Awaited 2026 Developments - AInvest
Viridian 2025 Q2 Earnings Wider Losses Amid Regulatory and Partnership Momentum - AInvest
Viridian Therapeutics Reports Q2 2025 Financial Results - TipRanks
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating - TipRanks
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments - TipRanks
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements - TipRanks
Viridian (VRDN) Q2 Net Loss Widens 55% - AOL.com
Viridian Therapeutics Q2 Net Loss Widens, Revenue Increases - MarketScreener
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Rises With Strong Cash And Clinical Progress - Finimize
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Viridian Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Viridian Therapeutics Q2 2025 Financial Results - TradingView
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $75,000, vs. FactSet Est of $100,000 - MarketScreener
Earnings Flash (VRDN) Viridian Therapeutics Posts Q2 Net Loss $1.00 a Share, vs. FactSet Est of $1.00 Loss - MarketScreener
Viridian Therapeutics shares rise 3.86% intraday after announcing inducement grants to new employees. - AInvest
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
What makes Viridian Therapeutics Inc. stock price move sharplyGet expert insights on market-moving stocks - Jammu Links News
When is Viridian Therapeutics Inc. stock expected to show significant growthStrong return on assets - Jammu Links News
What are the latest earnings results for Viridian Therapeutics Inc.Breakout portfolio performance - Jammu Links News
What is Viridian Therapeutics Inc. company’s growth strategyUnlock daily market insights for better trades - Jammu Links News
Is Viridian Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is it the right time to buy Viridian Therapeutics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
What analysts say about Viridian Therapeutics Inc. stockExplosive trading growth - Jammu Links News
How does Viridian Therapeutics Inc. compare to its industry peersMarket-leading capital gains - Jammu Links News
Why is Viridian Therapeutics Inc. stock attracting strong analyst attentionGet expert insights on market-moving stocks - Jammu Links News
What is the dividend policy of Viridian Therapeutics Inc. stockUnprecedented profit potential - Jammu Links News
How strong is Viridian Therapeutics Inc. company’s balance sheetGet timely market insights for better trades - jammulinksnews.com
What catalysts could drive Viridian Therapeutics Inc. stock higher in 2025Unprecedented market success - Jammu Links News
What institutional investors are buying Viridian Therapeutics Inc. stockAchieve superior returns through strategic trading - Jammu Links News
Viridian Therapeutics Collaborates with Kissei Pharmaceutical for Veligrotug and VRDN-003 Development in Japan - AInvest
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan - Yahoo Finance
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):